Last reviewed · How we verify
NCT06586177: REBELLION-MS
Understanding the 'Durable Effect' Concept of B-cell Modulating Therapies
trial testing Anti-CD20 antibody in Relapsing-remitting Multiple Sclerosis in 100 participants. Currently enrolling.
31 December 2028
Quick facts
| Lead sponsor | Heinrich-Heine University, Duesseldorf |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 27 October 2021 |
| Primary completion | 31 December 2028 |
| Estimated completion | 31 December 2028 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Anti-CD20 antibody — full drug profile →
Conditions studied
- Relapsing-remitting Multiple Sclerosis — all drugs for Relapsing-remitting Multiple Sclerosis →
Sponsor
Heinrich-Heine University, Duesseldorf
Who can join
Adults 18 to 60, any sex, with Relapsing-remitting Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This prospective, observational clinical study aims to longitudinally assess peripheral immune cell profiles of patients with relapsing-remitting multiple sclerosis (RRMS) receiving anti-CD20 therapy with ofatumumab (OFA), ocrelizumab (OCR), ublituximab (UBX), and rituximab (RTX). Throughout the study, clinical data - including relapse events, patient scores, and neuropsychological parameters - will be collected, along with results from imaging techniques such as Optical Coherence Tomography (OCT) and Magnetic Resonance Imaging (MRI). This clinical data will be combined with immunological analyses, including multidimensional flow cytometry (mFC), bulk RNA sequencing (bulk-Seq), T and B cell receptor sequencing (TCR/BCR-Seq), proteomics, and immunoglobulin analysis. This approach aims to enable a detailed characterization of changes in the immune cell repertoire and their impact on the clinical disease course.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effects of Anti-CD20 Antibody Therapy on Immune Cell Dynamics in Relapsing-Remitting Multiple Sclerosis.
Willison AG, Hagler R, Weise M, Elben S, et al · · 2025 · cited 4× · PMID 40214505 · DOI 10.3390/cells14070552
Verify or expand the search:
- PubMed search for NCT06586177
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Anti-CD20 antibody
Trials testing the same drug.
- NCT03155984 — Optimizing HBV Management During Anti-CD20 Antibodies · completed
Other recruiting trials for Relapsing-remitting Multiple Sclerosis
Currently open trials in the same condition.
- NCT05758831 — RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis. · Phase 3 · recruiting
- NCT05755061 — WEBCAMS: Walking Exercise for Brain and Cognition in Adults With Multiple Sclerosis · Phase 1 · active not recruiting
Other Heinrich-Heine University, Duesseldorf trials
Trials by the same sponsor.
- NCT04993508 — Randomized Prospective Multi Center Cohort Study for Primary Diagnosis of Clinically Significant Prostate Cancer With Co · NA · not yet recruiting
- NCT07385482 — Chronic and Acute Cardiovascular Diseases in Elderly Intensive Care Patients · not yet recruiting
- NCT07455097 — COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P) · active not recruiting
- NCT07254663 — GEL & MEDication Dysphagia · recruiting
- NCT06313944 — German Registry of Alzheimer's Disease Treated With Transcranial Pulse Stimulation · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06586177 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Heinrich-Heine University, Duesseldorf
- Last refreshed: 18 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06586177.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing